
**What is claimed is:**

1. A compound of formula (I)




(I)


or a pharmaceutically acceptable salt thereof, wherein:

$R^7$ is a peptide;


$R^8$ is selected from the group consisting of:




,




,




,


O
NH2
N
N
H
N


,



H
N
O
N
N
N
N
F
N
F


,



H
N
O
F
N
H
N


,



O
N
F
N
H
N
H



H
N
O
F
N
N
H


H
N
N
O
N
F
N



N
N
O
N
F
N
H


O
N
N
O
N
N
F
O



O
NH
N
O
O
N



O
N
O
O
S
N
N
N


,



NH2
N
O
N
N
O
S
O
N


,



NH
N
O
N
N
HN
O
S
O


O
Cl
N
O
N
F
N
N
N
O



N
N
N
D
N
D
N
N
O
HN


N
N
N
N
H
N
O
O
N
N



O
NH2
O
N
N+
F
F
F


H
N
O
O
N
H
N
H


;


H
N
O
O
NH2
N


;


O
NH2
F
N
N
H
N


;


O
NH
N
N+
P
O
F


;


O
N
N
N
P
O
F


;


O
O
N
N
O
NH2
N


;


N
N
O
N
N
O
NH2
F
N


;


O
N
O
N
N
O
NH2
N
N


;


N+
O
N
O
N
N
F
N


;


O
N
N
N
N
N
N
N


;


N
N
N
N
N
Cl
N
S
O
O

;





~~, and~~






;


~~Q is selected from the group consisting of~~






,



A
N
O
R1
R2
S
S
R5
R6
O
R4
R3



R5
R6
R1
R2
S
S
O
R4
R3



O
R5
R6
R1
R2
S
O
S
R4
R3



R9
R10
R6
R5
Aryl or
Hetaryl
R11
R12
[N,O,S]
O
R4
R3
S
S
O
R1
R2



R1
R2
R6
R5
Aryl or
Hetaryl
S
S
R3
R4


R9
R10
R6
R5
Aryl or
Hetaryl
R11
R12
O
N
H
[AA]x
H
N
O
O
R1
R2
S
S
R4
R3



R9
R10
R6
R5
Aryl or
Hetaryl
R11
R12
O
N
H
[AA]x
H
N
O
O
O
R1
R2
S
S
R4
R3


O
[AA]x
H
N
O
O
R1
R2
S
S
R4
R3



R2
S
R1
S
R5
R6
O
R3
[N,O]
R4
O
O
Aryl or
Hetaryl
R9
R12
R10
R11


R2
S
R1
S
O
R5
R6
O
R3
[C,N,O]
[N,O]
R4
O
Aryl or
Hetaryl
R9
R12
R10
R11


;



R1
R2
S
S
O
Aryl or
Hetaryl
R9
R12
R10
R11


;



O
R1
R2
[C,N,O]
S
S
Aryl or
Hetaryl
R9
R12
R10
R11


;



[N,O]
S
S
O
Aryl or
Hetaryl
R9
R12
R10
R11


R1
R2
S
[N,O]
S
O
Aryl or
Hetaryl
R9
R12
R10
R11



O
R5
R6
R9
O
R3
R4
O
[N,O]
S
S
R1
R2
R10
O
R11
S1


O
R5
R6
R9
R3
R4
R1
R2
H
N
S
S
O
O
R10
O
R11
S1



O
R5
R6
R9
H
N
R3
R4
S
S
O
R1
R2
R10
O
R11
S1


O
R5
R6
R9
R1
R2
O
S
S
O
R3
R4
R10
O
R11
S1


;


R5
R6
O
R4
R3
P
S
O
O
S
[N,O]
R13
R1
R2


;


R5
R6
O
R1
R2
P
S
O
O
Aryl or
Hetaryl
S
[N,O]
R13
R3
R4


;





;




;




~~, and~~




;

~~$R^1$, $R^2$, $R^3$, $R^4$, $R^5$, $R^6$, $R^9$, $R^{10}$, $R^{11}$, and $R^{12}$ are each independently selected from H, $C_{1-4}$ alkyl, $C_{1-4}$ alkenyl, $C_{6-10}$ aryl, 5-10 membered heteroaryl, halo, CN, $NO_2$, $OR^{a1}$, $SR^{a1}$, $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $OC(O)R^{b1}$, $OC(O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, and $NR^{c1}C(O)NR^{c1}R^{d1}$, wherein said $C_{1-4}$ alkyl, $C_{1-4}$ alkenyl, $C_{6-10}$ aryl, and 5-10 membered heteroaryl are each optionally substituted with 1, 2, or 3 substituents~~

independently selected from halo, CN, $NO_2$, $OR^{a1}$, $SR^{a1}$, $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $OC(O)R^{b1}$, $OC(O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, and $NR^{c1}C(O)NR^{c1}R^{d1}$;

or $R^1$ and $R^2$ together with the carbon atom to which they are attached form a $C_{3-7}$ cycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, $NO_2$, $OR^{a1}$, $SR^{a1}$, $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $OC(O)R^{b1}$, $OC(O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, and $NR^{c1}C(O)NR^{c1}R^{d1}$;


or $R^1$ and $R^3$ together with the carbon atom to which they are attached form a $C_{3-7}$ cycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, $NO_2$, $OR^{a1}$, $SR^{a1}$, $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $OC(O)R^{b1}$, $OC(O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, and $NR^{c1}C(O)NR^{c1}R^{d1}$;

or $R^3$ and $R^4$ together with the carbon atom to which they are attached form an $C_{3-7}$ cycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, $NO_2$, $OR^{a1}$, $SR^{a1}$, $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $OC(O)R^{b1}$, $OC(O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, and $NR^{c1}C(O)NR^{c1}R^{d1}$;

or $R^5$ and $R^6$ together with the carbon atom to which they are attached form an $C_{3-7}$ cycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, $NO_2$, $OR^{a1}$, $SR^{a1}$, $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $OC(O)R^{b1}$, $OC(O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, and $NR^{c1}C(O)NR^{c1}R^{d1}$

$R^{13}$ is H or $C_{1-6}$ alkyl;

A is H or $C_{1-4}$ alkyl;




is $C_{6-10}$ aryl or 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S;


[N, O, S] is NH, O, or S;

[N, O] is NH or O;

[C, N, O] is $CR^XR^Y$, NH, or O;

each $R^X$ and $R^Y$ are independently selected from H and $C_{1-4}$ alkyl;

$[AA]_X$ is a peptide that may be cleaved by enzymatic action;

S1 is  ;

each $R^a$, $R^b$, $R^c$, and $R^d$ are independently selected from H, $C_{1-4}$ alkyl, $OR^{a2}$, $CO_2R^{a2}$, and $OC(=O)R^{a2}$, wherein said $C_{1-4}$ alkyl is optionally substituted with $OR^{a2}$, $CO_2R^{a2}$, and $OC(=O)R^{a2}$;

$R^{a1}$, $R^{b1}$, $R^{c1}$, and $R^{d1}$ are each independently selected from H, $C_{1-6}$ alkyl, $C_{2-6}$ alkenyl, $C_{2-6}$ alkynyl, $C_{1-6}$ haloalkyl, OH, CN, $NO_2$, and $CO_2CH_3$; wherein said $C_{1-6}$ alkyl and $C_{2-6}$ alkenyl are each optionally substituted with OH, CN, $NO_2$, or $CO_2CH_3$;

$R^{a2}$ is H or $C_{1-4}$ alkyl; and

n is 0 or 1.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein $R^7$ is a peptide capable of selectively delivering $R^8Q$ across a cell membrane having an acidic or hypoxic mantle having a pH less than about 6.0.

3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein $R^7$ is a peptide comprising at least one of the following sequences:

ADDQNPWRAYLDLLFPTDTLLLDLLWCG (SEQ ID NO: 1; Pv1);

AEQNPIYWARYADWLFTTPLLLLDLALLVDADECG (SEQ ID NO: 2; Pv2);

ADDQNPWRAYLDLLFPTDTLLLDLLWDADECG (SEQ ID NO: 3; Pv3);

Ac-AAEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTKCG (SEQ ID NO: 4; Pv4); and

AAEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTC (SEQ ID No. 5; Pv5); and wherein $R^7$ is attached to Q through a cysteine residue of $R^7$.

4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein $R^7$ is a peptide comprising at least one of the following sequences:

~~ADDQNPWRAYLDLLFPTDTLLLDLLWCG (SEQ ID NO: 1; Pv1),~~

~~AEQNPIYWARYADWLFTTPLLLLDLALLVDADECG (SEQ ID NO: 2; Pv2), and~~

~~ADDQNPWRAYLDLLFPTDTLLLDLLWDADECG (SEQ ID NO: 3; Pv3),~~

~~and wherein $R^7$ is attached to Q through a cysteine residue of $R^7$.~~

~~5. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein $R^7$ is a peptide comprising the sequence: ADDQNPWRAYLDLLFPTDTLLLDLLWCG (SEQ ID NO: 1; Pv1).~~

~~6. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein $R^7$ is a peptide comprising the sequence: AEQNPIYWARYADWLFTTPLLLLDLALLVDADECG (SEQ ID NO: 2; Pv2).~~

~~7. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein $R^7$ is a peptide comprising the sequence: ADDQNPWRAYLDLLFPTDTLLLDLLWDADECG (SEQ ID NO: 3; Pv3).~~

~~8. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein $R^7$ is a peptide comprising the sequence: Ac-AAEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTKCG (SEQ ID NO: 4; Pv4).~~

~~9. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein $R^7$ is a peptide comprising the sequence: AAEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTC (SEQ ID No. 5; Pv5).~~

~~10. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein $R^1$ and $R^2$ are each independently selected from H and methyl, and $R^3$, $R^4$, $R^5$, and $R^6$ are each H.~~

~~11. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein $R^1$ and $R^2$ are each independently selected from H and methyl.~~

12. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein $R^1$ and $R^2$ are each H.

13. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein $R^3$ and $R^4$ are each H.

14. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein $R^5$ and $R^6$ are each H.


15. The compound of any one of claims 1-14, or a pharmaceutically acceptable salt thereof, wherein $R^9$, $R^{10}$, $R^{11}$, and $R^{12}$ are each independently selected from H and methyl.

16. The compound of any one of claims 1-15, or a pharmaceutically acceptable salt thereof, wherein the enzyme capable of cleaving $[AA]_x$ is Cathepsin B, MMPXX, DPPIV, glycoprotein, peptidase, or caspase.


17. The compound of any one of claims 1-15, or a pharmaceutically acceptable salt thereof, wherein [AA]x is a peptide having two to ten amino acid residues.

18. The compound of any one of claims 1-15, or a pharmaceutically acceptable salt thereof, wherein $[AA]_x$ is -Pro_Gly-; -Val_Cit-, -Gly_Pro_Leu_Gly_Leu_Ala_Gly_Asp_Asp-, -Gly_Pro_GLeu_Gly_Val_Arg_Gly, or -Ser_Ser_Lys_Leu_Gly-.


19. The compound of any one of claims 1-18, or a pharmaceutically acceptable salt thereof, wherein S1 is a group having the following structure:




20. ~~The compound of claim 1, or a pharmacetucailly acceptable salt thereof, which is selected from:~~




;




;




;


NH
N
O
NH2
O
O
O
S
S
Pv3


;


NH
N
O
NH2
O
O
O
S
S
Pv3


;


NH
N
O
NH2
O
O
O
S
S
Pv3


;


NH
N
O
NH2
O
O
O
S
S
Pv3


;


OH
O
O
O
O
S
S
Pv2
N
O


;


OH
O
O
O
O
S
S
Pv3
N
O


;


NH2
O
N
N
N
O
O
S
S
Pv3


;


NH2
O
N
N
O
S
S
Pv3
N
H
O


;


F
N
N
N
O
S
S
Pv2
N
N
H
O
N
HN
F
O


;


F
N
N
N
O
N
H
O
S
S
Pv2
N
HN
O
F


;


F
N
N
N
O
N
H
O
S
S
Pv2
N
HN
O
F


;—


H
N
O
F
N
H
N
O
O
S
S
Pv2


;


F
N
N
N
O
S
Pv1
N
H
O
N
HN
F
O


;


F
N
N
N
O
S
Pv3
N
H
O
N
HN
F
O


;


O
HN
N
O
S
S
Pv1
O
NH
F


;


HN
O
NH
F
N
O
O
S
S
Pv2


;


HN
O
NH
F
N
O
O
S
S
Pv3


;


HN
O
NH
F
N
O
O
S
S
Pv1


;


HN
O
NH
F
N
O
O
S
S
Pv2


;


HN
O
NH
F
N
O
O
S
S
Pv3


;


HN
O
NH
F
N
O
O
S
S
Pv3


;


HN
O
NH
F
N
O
O
S
S
Pv2


;


HN
O
NH
F
N
O
O
O
O
S
S
Pv2


;


HN
O
NH
F
N
O
O
O
O
S
S
Pv2


;


HN
O
NH
F
N
O
O
O
S
S
Pv2


;


HN
O
O
N
O
S
S
Pv2
NH
F


;


HN
O
O
N
O
S
S
Pv2
NH
F


;



HN
O
O
N
O
S
S
Pv2
NH
F


;



HN
O
O
N
O
O
N
H
O
S
S
Pv2
NH
F

;



HN
O
N
H
N
H
N
O
O
F
S
S
Pv2


HN
O
N
H
N
H
N
O
O
F
S
S
Pv2



HN
O
N
H
N
H
N
O
O
F
S
S
Pv2


HN
O
NH
F
N
O
O
S
S
Pv1


;


HN
O
NH
F
N
O
O
S
S
Pv3


;


H
N
N
O
N
F
N
H
N
O
O
S
S
Pv2


;


F
N
N
N
O
S
Pv2
N
N
H
O
S
N
HN
F
O


;


F
N
N
N
O
S
Pv1
N
N
H
O
S
N
HN
F
O


;


F
N
N
N
O
S
S
Pv3
N
H
O
N
HN
F
O


;


F
N
N
N
O
S
S
Pv1
N
H
O
N
HN
F
O


;


F
N
N
N
O
S
S
Pv3
N
H
O
N
HN
F
O


;


O
HN
N
O
S
S
Pv1
O
NH
F


;



NH2
O
N
N
N
O
O
S
S
Pv3


;



NH2
O
N
N
N
O
O
S
S
Pv3


;


NH2
O
N
N
O
O
S
S
Pv2



NH2
O
N
N
O
O
S
S
Pv2


NH2
O
N
N
O
O
S
S
Pv2



NH2
O
N
N
O
O
S
S
Pv2


NH2
O
N
N
O
S
S
Pv3
O
N
H


;


NH2
O
N
N
O
S
S
Pv3
O
N
H


;


NH2
O
N
N
O
S
S
Pv2
O
N
H


;


NH2
O
N
N
O
S
S
Pv2
O
N
H


;


NH2
O
N
N
O
S
S
Pv2
O
N
H


;


NH2
O
N
N
O
O
N
H
S
S
Pv3


;


O
HN
O
N
O
S
S
Pv4
NH
F


;


O
HN
O
N
O
S
S
Pv5
NH
F


;


S
S
Pv2
O
HN
O
N
O
NH
F


;


NH
N
O
NH2
O
O
S
S
Pv2


;


NH
N
O
NH2
O
O
O
S
S
Pv2

;



HN
O
NH
F
O
N
O
O
N
H
O
H
N
O
N
H
O
O
S
S
Pv2
O
NH
NH2

;


HN
O
NH
F
O
N
O
N
O
O
N
H
O
S
S
Pv2

;

and




21. A pharmaceutical composition that comprises a compound of any one of claims 1-20, or a pharmaceutically acceptable salt thereof.

22. A method of treating a disease or condition involving acidic or hypoxic diseased tissue in an afflicted human or other mammal in need of such treatment which comprises administering to the afflicted human or other mammal a therapeutically-effective amount of the compound of any one of claims 1-20, or a pharmaceutically acceptable salt thereof.

23. The method of claim 22, wherein the disease or condition is selected from cancer, stroke, myocardial infarction, and long-term neurodegenerative disease.

24. The method of claim 23, wherein the disease or condition is cancer.

25. The method of claim 24, wherein the cancer is PARP-sensitive.

26. The method ofclaim 24, wherein the cancer is associated with abnormal expression or activity of ATM.

27. The method of claim 24, wherein the cancer is associated with abnormal expression or activity of DNA-PK.


28. The method of claim 24, wherein the cancer is BRCA-mutated breast cancer.

~~29. The method of claim 24, wherein the cancer is germline BRCA-mutated ovarian cancer.~~

~~30. The method of claim 23, which further comprises administering a therapeutically-effective amount of ionizing radiation or a cytotoxic agent to said afflicted human or other mammal.~~

~~31. A method of reducing bone marrow toxicity associated with administration of an ionizing radiation or cytotoxic agent, which comprises administering to a human or other mammal a therapeutically-effective amount of the compound of any one of claims 1-20, or a pharmaceutically acceptable salt thereof, in combination with the ionizing radiation or cytotoxic agent.~~

1. A compound of formula (I)





(I)


or a pharmaceutically acceptable salt thereof, wherein:

$R^7$ is a peptide;


$R^8$ is selected from the group consisting of:




,





, and





,


Q is selected from the group consisting of





,





,


R5
R6
R1
R2
S
S
O
R4
R3


,


O
R5
R6
R1
R2
S
O
S
R4
R3


,


R9
R10
R6
R5
Aryl or
Hetaryl
[N,O,S]
O
R4
R3
S
O
S
R1
R2
R11
R12


,



R1
R2
R6
R5
Aryl or
Hetaryl
S
S
R3
R4


,



R9
R10
O
R6
R1
R2
R5
Aryl or
Hetaryl
N
H
[AA]x
H
N
O
S
S
O
R4
R3
R11
R12

,



R9
R10
R6
R5
Aryl or
Hetaryl
O
N
H
[AA]x
H
N
O
R1
R2
S
S
O
R4
R3
R11
R12


O
[AA]x
H
N
O
R1
R2
S
S
O
R4
R3



R2
S
R1
S
R5
R6
O
R3
[N,O]
R4
O
O
Aryl or
Hetaryl
R9
R12
R10
R11


R2
S
R1
S
O
R5
R6
O
R3
[C,N,O]
[N,O]
R4
O
Aryl or
Hetaryl
R9
R12
R10
R11


,



R1
R2
S
S
O
Aryl or
Hetaryl
R9
R12
R10
R11


,



O
R1
R2
[C,N,O]
S
S
Aryl or
Hetaryl
R9
R12
R10
R11


,



[N,O]
S
S
O
Aryl or
Hetaryl
R9
R12
R10
R11



R1
R2
S
[N,O]
S
O
Aryl or
Hetaryl
R9
R12
R10
R11



O
R5
R6
R9
O
R3
R4
S
S
O
[N,O]
R1
R2
R10
O
R11
S1



O
R5
R6
R9
R3
R4
R1
R2
H
N
S
S
O
O
R10
O
R11
S1


O
R5
R6
R9
H
N
R3
R4
S
S
O
R1
R2
R10
O
R11
S1



O
R5
R6
R9
R1
R2
O
S
S
O
R3
R4
R10
O
R11
S1


R5
R6
O
R4
R3
P
S
O
O
S
[N,O]
R13
R1
R2



R5
R6
O
R1
R2
P
S
O
O
Aryl or
Hetaryl
S
[N,O]
R13
R3
R4





,




,




, and




;

$R^1$, $R^2$, $R^3$, $R^4$, $R^5$, $R^6$, $R^9$, $R^{10}$, $R^{11}$, and $R^{12}$ are each independently selected from H, $C_{1-4}$ alkyl, $C_{1-4}$ alkenyl, $C_{6-10}$ aryl, 5-10 membered heteroaryl, halo, CN, $NO_2$, $OR^{a1}$, $SR^{a1}$, $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $OC(O)R^{b1}$, $OC(O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, and $NR^{c1}C(O)NR^{c1}R^{d1}$, wherein said $C_{1-4}$ alkyl, $C_{1-4}$ alkenyl, $C_{6-10}$ aryl, and 5-10 membered heteroaryl are each optionally substituted with 1, 2, or 3 substituents

independently selected from halo, CN, $NO_2$, $OR^{a1}$, $SR^{a1}$, $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $OC(O)R^{b1}$, $OC(O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, and $NR^{c1}C(O)NR^{c1}R^{d1}$;

or $R^1$ and $R^2$ together with the carbon atom to which they are attached form a $C_{3-7}$ cycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, $NO_2$, $OR^{a1}$, $SR^{a1}$, $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $OC(O)R^{b1}$, $OC(O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, and $NR^{c1}C(O)NR^{c1}R^{d1}$;


or $R^1$ and $R^3$ together with the carbon atom to which they are attached form a $C_{3-7}$ cycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, $NO_2$, $OR^{a1}$, $SR^{a1}$, $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $OC(O)R^{b1}$, $OC(O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, and $NR^{c1}C(O)NR^{c1}R^{d1}$;

or $R^3$ and $R^4$ together with the carbon atom to which they are attached form an $C_{3-7}$ cycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, $NO_2$, $OR^{a1}$, $SR^{a1}$, $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $OC(O)R^{b1}$, $OC(O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, and $NR^{c1}C(O)NR^{c1}R^{d1}$;

or $R^5$ and $R^6$ together with the carbon atom to which they are attached form an $C_{3-7}$ cycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, $NO_2$, $OR^{a1}$, $SR^{a1}$, $C(O)R^{b1}$, $C(O)NR^{c1}R^{d1}$, $C(O)OR^{a1}$, $OC(O)R^{b1}$, $OC(O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(O)R^{b1}$, $NR^{c1}C(O)OR^{a1}$, and $NR^{c1}C(O)NR^{c1}R^{d1}$;

$R^{13}$ is H or $C_{1-6}$ alkyl;

A is H or $C_{1-4}$ alkyl;




is $C_{6-10}$ aryl or 5-10 membered heteroaryl; wherein the 5-10 membered heteroaryl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S;


[N, O, S] is NH, O, or S;

[N, O] is NH or O;

[C, N, O] is $CR^XR^Y$, NH, or O;

each $R^X$ and $R^Y$ is independently selected from H and $C_{1-4}$ alkyl;

$[AA]_X$ is a peptide that may be cleaved by enzymatic action;




S1 is ; each $R^a$, $R^b$, $R^c$, and $R^d$ is independently selected from H, $C_{1-4}$ alkyl, $OR^{a2}$, $CO_2R^{a2}$, and $OC(=O)R^{a2}$, wherein said $C_{1-4}$ alkyl is optionally substituted with $OR^{a2}$, $CO_2R^{a2}$, and $OC(=O)R^{a2}$;

$R^{a1}$, $R^{b1}$, $R^{c1}$, and $R^{d1}$ are each independently selected from H, $C_{1-6}$ alkyl, $C_{2-6}$ alkenyl, $C_{2-6}$ alkynyl, $C_{1-6}$ haloalkyl, OH, CN, $NO_2$, and $CO_2CH_3$; wherein said $C_{1-6}$ alkyl and $C_{2-6}$ alkenyl are each optionally substituted with OH, CN, $NO_2$, or $CO_2CH_3$;

$R^{a2}$ is H or $C_{1-4}$ alkyl; and

n is 0 or 1.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein $R^7$ is a peptide capable of selectively delivering $R^8Q$- across a cell membrane having an acidic or hypoxic mantle having a pH less than about 6.0.

3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein $R^7$ is a peptide comprising at least one of the following sequences:

ADDQNPWRAYLDLLFPTDTLLLDLLWCG (SEQ ID NO: 1; Pv1);

AEQNPIYWARYADWLFTTPLLLLDLALLVDADECG (SEQ ID NO: 2; Pv2);

ADDQNPWRAYLDLLFPTDTLLLDLLWDADECG (SEQ ID NO: 3; Pv3);

Ac-AAEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTKCG (SEQ ID NO: 4; Pv4); and

AAEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTC (SEQ ID No. 5; Pv5); and wherein $R^7$ is attached to Q through a cysteine residue of $R^7$.

4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein $R^7$ is a peptide comprising at least one of the following sequences:

ADDQNPWRAYLDLLFPTDTLLLDLLWCG (SEQ ID NO: 1; Pv1),
AEQNPIYWARYADWLFTTPLLLLDLALLVDADECG (SEQ ID NO: 2; Pv2), and
ADDQNPWRAYLDLLFPTDTLLLDLLWDADECG (SEQ ID NO: 3; Pv3),
and wherein $R^7$ is attached to Q through a cysteine residue of $R^7$.

5. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein $R^7$ is a peptide comprising the sequence: ADDQNPWRAYLDLLFPTDTLLLDLLWCG (SEQ ID NO: 1; Pv1).

6. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein $R^7$ is a peptide comprising the sequence: AEQNPIYWARYADWLFTTPLLLLDLALLVDADECG (SEQ ID NO: 2; Pv2).

7. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein $R^7$ is a peptide comprising the sequence: ADDQNPWRAYLDLLFPTDTLLLDLLWDADECG (SEQ ID NO: 3; Pv3).

8. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein $R^7$ is a peptide comprising the sequence: Ac-AAEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTKCG (SEQ ID NO: 4; Pv4).

9. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein $R^7$ is a peptide comprising the sequence: AAEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTC (SEQ ID No. 5; Pv5).

10. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein $R^1$ and $R^2$ are each independently selected from H and methyl, and $R^3$, $R^4$, $R^5$, and $R^6$ are each H.

11. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein $R^1$ and $R^2$ are each independently selected from H and methyl.

12. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein $R^1$ and $R^2$ are each H.

13. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein $R^3$ and $R^4$ are each H.


14. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein $R^5$ and $R^6$ are each H.

15. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein $R^9$, $R^{10}$, $R^{11}$, and $R^{12}$ are each independently selected from H and methyl.

16. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the enzyme capable of cleaving $[AA]_X$ is Cathepsin B, MMPXX, DPPIV, glycoprotein, peptidase, or caspase.

17. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein [AA]x is a peptide having two to ten amino acid residues.


18. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein S1 is a group having the following structure:




.


19. A pharmaceutical composition that comprises a compound of claim 1, or a pharmaceutically acceptable salt thereof.

20. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R8 is:



.

21. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Q is:




.

22. The compound of claim 21, or a pharmaceutically acceptable salt thereof, wherein $R^1$ and $R^2$ are each independently selected from H and methyl.

23. The compound of claim 21, or a pharmaceutically acceptable salt thereof, wherein $R^3$ and $R^4$ are each H.

24. A compound, which is:




,

or a pharmaceutically acceptable salt thereof; wherein Pv1 is a peptide comprising the following sequence:

ADDQNPWRAYLDLLFPTDTLLLDLLWCG (SEQ ID NO: 1).

25. A compound, which is:





,

or a pharmaceutically acceptable salt thereof; wherein Pv1 is a peptide comprising the following sequence:

ADDQNPWRAYLDLLFPTDTLLLDLLWCG (SEQ ID NO: 1).

26. A compound, which is:




,

or a pharmaceutically acceptable salt thereof; wherein Pv2 is a peptide comprising the following sequence:

AEQNPIYWARYADWLFTTPLLLLDLALLVDADECG (SEQ ID NO: 2).

27. A pharmaceutical composition comprising a compound of claim 24, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

28. A pharmaceutical composition comprising a compound of claim 25, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

29. A pharmaceutical composition comprising a compound of claim 26, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.